We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+18.79%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$776M
AUM Growth
+$70.2M
Cap. Flow
+$109M
Cap. Flow %
14.05%
Top 10 Hldgs %
67%
Holding
41
New
7
Increased
5
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$27.8M
2
TCDA
Tricida, Inc. Common Stock
TCDA
+$27.7M
3
LITS
Lite Strategy Inc
LITS
+$20.2M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$12.3M
5
ZYME icon
Zymeworks
ZYME
+$9.61M

Top Sells

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$9.77M
2
RNAC icon
Cartesian Therapeutics
RNAC
+$4M
3
RGNX icon
Regenxbio
RGNX
+$3.92M
4
ZLAB icon
Zai Lab
ZLAB
+$1.14M
5
APLS
Apellis Pharmaceuticals
APLS
+$30.7K

Sector Composition

Rank Sector Weight
1 Healthcare 97.57%
2 Materials 2.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNCA
26
DELISTED
Genocea Biosciences, Inc.
GNCA
$7M 0.9%
1,022,500
– –
AUPH icon
27
Aurinia Pharmaceuticals
AUPH
$1.92B
$6.83M 0.88%
1,213,290
– –
RGNX icon
28
Regenxbio
RGNX
$616M
$5.91M 0.76%
82,403
-82,000
-50% -$3.92M
ZLAB icon
29
Zai Lab
ZLAB
$2.06B
$5.37M 0.69%
231,010
-52,777
-19% -$1.14M
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$4.64M 0.6%
105,000
– –
FOMX
31
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.28M 0.55%
855,000
– –
TMBR
32
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$3.56M 0.46%
1,075
– –
KNSA icon
33
Kiniksa Pharmaceuticals
KNSA
$6.12B
$3.23M 0.42%
+186,073
New +$3.37M
VRNA
34
DELISTED
Verona Pharma
VRNA
$2.79M 0.36%
1,492,951
– –
TRVN
35
DELISTED
Trevena, Inc.
TRVN
$2.49M 0.32%
2,765
– –
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$2.44M 0.31%
300,325
– –
AGRX
37
DELISTED
Agile Therapeutics
AGRX
$742K 0.1%
757
– –
AKTX
38
Akari Therapeutics
AKTX
$14.3M
$674K 0.09%
432
– –
VIRX
39
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$414K 0.05%
5,585
– –
SLNOW
40
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$79K 0.01%
188,772
– –
AIMT
41
DELISTED
Aimmune Therapeutics
AIMT
– –
-306,872
Closed -$9.77M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Vivo Capital held 41 positions worth $776M, up 9.9% from $706M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Vivo Capital deployed $109M of net new capital in Q2 2018, opening 7 new positions and adding to 5 existing holdings. Its largest new stake was Tricida, Inc. Common Stock: 991,711 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 95% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Cartesian Therapeutics, an estimated $4M trimmed.

  • Vivo Capital's largest Q2 2018 buy was Tricida, Inc. Common Stock: 991,711 shares worth $29.7M.
  • Vivo Capital added most to Kadmon Holdings, Inc. in Q2 2018, an estimated $27.8M increase.
  • Vivo Capital's biggest Q2 2018 reduction was Cartesian Therapeutics, cutting an estimated $4M.
  • Vivo Capital fully exited Aimmune Therapeutics in Q2 2018, selling an estimated $9.77M.
  • Vivo Capital's ten largest holdings make up 67% of its $776M portfolio in Q2 2018.
  • Vivo Capital opened 7 new positions and closed 1 in Q2 2018.
  • Vivo Capital's portfolio value rose 9.9% quarter-over-quarter to $776M.

Based on Vivo Capital's 13F filing for Q2 2018, filed 10 Aug 2018.